Not Just Another Index.
It’s The New Generation.®
We offer specialized solutions for investors seeking exposure to New Listings - a proxy for economic growth and innovation.
New: The IPOX® High Dividend 7% Strategy
An Innovative Index Strategy
combining Income & Growth!
Upcoming Global IPOs
The IPOX® Newsletters
IPOX® in the News
In a recent Reuters article, IPOX® VP Kat Liu commented on travel tech firm Navan’s $923 million Nasdaq debut, highlighting the growing investor interest in AI-driven IPOs. Liu noted that, “For Navan to be a true credible AI story, it needs to demonstrate some unique and hard-to-replicate value.” Her remarks underscore IPOX’s continued insight into how innovation and authenticity shape success in today’s evolving IPO market.
Reuters highlights Medline’s blockbuster U.S. IPO filing, which could value the healthcare giant at up to $50 billion. Commenting on the deal, IPOX® Research Associate Lukas Muehlbauer said the offering “signals that the IPO market remains wide open despite the shutdown” and will serve as a key test of investor confidence heading into 2026. Medline’s listing, expected to be one of the year’s largest, underscores renewed strength in the U.S. IPO market after several years of subdued activity.
Reuters features IPOX® Research Associate Lukas Muehlbauer commenting on the biotech IPO rebound following MapLight Therapeutics’ $787 million Nasdaq debut. Muehlbauer notes that while the market is “slowly thawing,” many 2021–2023 listings still trade below offer prices, creating challenges for early-stage biotech firms seeking investor confidence.
Earnings season is in full swing, with U.S. banks kicking off the reporting cycle and key IPOX® Index constituents set to follow. Next week will feature major updates from leading firms across the IPOX® 100 U.S., IPOX® Europe, and IPOX® International indexes — including GE Vernova, IBM, Nextracker, MilDef, Porsche, and CATL — offering valuable insight into global sector performance and momentum across IPOX® portfolios.
In a Reuters article on Navan’s planned $6.45 billion U.S. IPO, IPOX® CEO Josef Schuster commented on the impact of the ongoing U.S. government shutdown on IPO sentiment. Schuster noted that while optimism remains, “heightened volatility” and regulatory delays may weigh on demand, urging issuers to remain flexible with offering terms.
The IPOX® Update
In the U.S., a potential Fannie Mae IPO by late 2025 and WestJet’s planned listing highlight optimism despite the government shutdown halting DeepGreenX’s debut. Europe sees EDF exploring a €7–10B Edison IPO and Poland’s Empik eyeing €200M. Asia-Pacific dominates with Yangtze Memory’s possible $40B listing, Haier’s $500M IoT spinout, and multiple Hong Kong, Singapore, and Tokyo deals. In MENA, Dubizzle postponed its $2B Dubai IPO amid weak market sentiment.
IPO activity accelerates despite the U.S. government shutdown. In the U.S., Medline targets a ~$5B float, PayPay eyes a December listing above $20B, Navan and Beta advance sizable offerings, and Exzeo launches on NYSE. Europe sees CSG and Shawbrook preparing deals, while Asia-Pacific features Seres, WeRide, Rakuten Card, Coca-Cola’s HCCB, and I-Mab’s dual listing. MENA’s Dubizzle opens a ~$600M Dubai IPO. IPOX® CEO Josef Schuster urges flexible terms amid volatility.
Global IPO activity is accelerating across regions, led by biotech and AI firms in the U.S., major industrial listings in Europe, and robotics and infrastructure plays in Asia. MENA markets also see renewed momentum with Dubai and Johannesburg offerings on deck. Commentary from IPOX® CEO Josef Schuster and IPOX® Analyst Lukas Muehlbauer underscores strong investor sentiment and strategic timing as issuers navigate regulatory hurdles and capitalize on market windows.